Is there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004-2011

Basit Öğe Kaydı
dc.contributor.authorPullukcu, Husnu
dc.contributor.authorAydemir, Sohret
dc.contributor.authorTasbakan, Meltem Isikgoz
dc.contributor.authorSipahi, Oguz Resat
dc.contributor.authorHall, Feriha Cilli, Jr.
dc.contributor.authorTunger, Alper
dc.date.accessioned2019-10-27T21:42:47Z
dc.date.available2019-10-27T21:42:47Z
dc.date.issued2013
dc.departmentEge Üniversitesien_US
dc.description.abstractAim: Resistance patterns of Escherichia coli to fosfomycin, ciprofloxacin, amikacin, and cotrimoxazole were evaluated in 2 different studies held in 2004 and 2005. In this study, it was aimed to compare the changes in the susceptibility patterns of uropathogenic E. coli strains to the above-mentioned antibiotics after 6 years. Materials and methods: Between February and April 2011, E. coli strains isolated from urine samples were included prospectively in the study. Results: A total of 502 E. coli strains (358 from outpatients and 144 from inpatients) were isolated from urine specimens between February and April 2011. Extended spectrum beta-lactamase (ESBL)-producer E. coli rate was 35%. Resistances to cotrimoxazole, ciprofloxacin, amikacin, and fosfomycin were 54.5%, 49.8%, 22.7%, and 1.4%, respectively. When we compared ESBL-producer E. coli strains isolated in 2005 and 2011, amikacin resistance increased (11% to 22.7%, P = 0.0001), whereas cotrimoxazole resistance decreased significantly (74% to 62.9%, P = 0.0063). When we compared resistance patterns of non-ESBL-producer E. coli in relation to 2004 and 2011, there was no significant change in the resistance to fosfomycin, cotrimoxazole, ciprofloxacin, and amikacin. Pooled analysis of fosfomycin studies from Turkey revealed 1.6% fosfomycin resistance in a total of 6439 strains. Conclusion: Our results suggest that despite common usage, there is not an increase in the resistance to fosfomycin. We conclude that fosfomycin can be used as one of the primary choices in the empirical therapy of urinary tract infections.en_US
dc.identifier.doi10.3906/sag-1210-75
dc.identifier.endpage541en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue4en_US
dc.identifier.startpage537en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1210-75
dc.identifier.urihttps://hdl.handle.net/11454/46963
dc.identifier.volume43en_US
dc.identifier.wosWOS:000323609800008en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectResistanceen_US
dc.subjectfosfomycinen_US
dc.subjecturinary tract infectionen_US
dc.titleIs there a rise in resistance rates to fosfomycin and other commonly used antibiotics in Escherichia coli-mediated urinary tract infections? A perspective for 2004-2011en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu